Cargando…

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder

The present study aims to describe a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this induction phase. METHODS: The induction protocol and associated data on opioi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oviedo-Joekes, Eugenia, Palis, Heather, Guh, Daphne, Marsh, David C., MacDonald, Scott, Harrison, Scott, Brissette, Suzanne, Anis, Aslam H., Schechter, Martin T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791495/ https://www.ncbi.nlm.nih.gov/pubmed/30747750 http://dx.doi.org/10.1097/ADM.0000000000000505

Ejemplares similares

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder()
por: Palis, Heather, et al.
Publicado: (2018)

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency
por: Marchand, Kirsten I, et al.
Publicado: (2011)

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
por: Palis, Heather, et al.
Publicado: (2017)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2012)

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users
por: Marchand, Kirsten, et al.
Publicado: (2015)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2020)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
por: Palis, Heather, et al.
Publicado: (2021)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
por: Fikowski, Jill, et al.
Publicado: (2014)

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2021)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Patient-centred care for addiction treatment: a scoping review protocol
por: Marchand, Kirsten, et al.
Publicado: (2018)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
por: Marchand, Kirsten, et al.
Publicado: (2019)

Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index
por: Perea-Milla, Emilio, et al.
Publicado: (2009)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
por: Jaffe, Kaitlyn, et al.
Publicado: (2023)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

Striatal resting-state connectivity after long-term diacetylmorphine treatment in opioid-dependent patients
por: Schaub, Anna-Chiara, et al.
Publicado: (2022)

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
por: Allen, Sean T., et al.
Publicado: (2023)

Morphine versus Hydromorphone: Does Choice of Opioid Influence Outcomes?
por: Gulur, Padma, et al.
Publicado: (2015)

Hydromorphone-Induced Tactile Hallucinations: Rare Opioid Side Effect
por: Kiyokawa, Miki, et al.
Publicado: (2021)

Morphine‐induced cutaneous adverse drug reaction following occupational diacetylmorphine contact dermatitis: A case report
por: van den Hoed, Ewoud, et al.
Publicado: (2019)

Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on mood, opioid adverse effects, and recovery
por: Yang, Yanqing, et al.
Publicado: (2018)

NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America
por: Gartry, Candice C, et al.
Publicado: (2009)

Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids
por: Oldenmenger, Wendy H., et al.
Publicado: (2011)

A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study
por: Trujols, Joan, et al.
Publicado: (2014)

Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment
por: Meyer, Maximilian, et al.
Publicado: (2022)

Effects of Maropitant Citrate or Acepromazine on the Incidence of Adverse Events Associated with Hydromorphone Premedication in Dogs
por: Claude, A.K., et al.
Publicado: (2014)

Acute suicidal ideations responsive to hydromorphone
por: Rotchford, James Kimber
Publicado: (2019)

Unintentional administration of intra‐articular hydromorphone
por: Doyle, Stephen, et al.
Publicado: (2021)

Analgosedation: The Use of Fentanyl Compared to Hydromorphone
por: Choi, Hahnl, et al.
Publicado: (2021)

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers
por: Labonté, Laura E., et al.
Publicado: (2021)

CaMKII regulates the proteins TPM1 and MYOM2 and promotes diacetylmorphine-induced abnormal cardiac rhythms
por: Ji, Min, et al.
Publicado: (2023)

Mycobacteremia from Crushed Hydromorphone Tablet Injection
por: Banno, Joseph M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pvsqfmbbqb54dgt6idubsl024d